Jung Hae Hyuk
Department of Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Republic of Korea.
Kidney Res Clin Pract. 2022 Sep;41(5):567-579. doi: 10.23876/j.krcp.22.005. Epub 2022 May 4.
Certain pharmacotherapies have shown to be effective for both cardiac and kidney outcomes. Although risk prediction is important in treatment decision-making, few studies have evaluated prediction models for composite cardiovascular and kidney outcomes.
This study included 2,195,341 Korean adults from a nationwide cohort for chronic kidney disease and a representative sample of the general population, with a 9-year follow-up. This study evaluated prediction models for a composite of major cardiovascular events or kidney disease progression that included albuminuria and estimated glomerular filtration rate (eGFR) and/or traditional cardiovascular disease predictors.
The addition of albuminuria and eGFR to a model for the composite outcome that included age, sex, and traditional predictors increased a C statistic by 0.0459, while the addition of traditional predictors to age, sex, albuminuria, and eGFR increased a C statistic by 0.0157. When age and sex-adjusted incidence rates were calculated across the combined Pooled-Cohort-Equations (PCEs) and Kidney Disease: Improving Global Outcomes (KDIGO) risk categories in diabetic or hypertensive participants, the incidence of ≥10 per 1,000 person-years was observed among all categories with high or very high KDIGO risk and among categories with moderate (or low) KDIGO risk and a PCEs 10-year risk of ≥10% (or ≥20%), accounting for 36% of diabetic and 18% of hypertensive populations.
This study strongly supports the utility of the KDIGO risk matrix combined with a conventional cardiovascular risk score for the prediction of composite cardiovascular and kidney outcome and provides epidemiologic data relevant to the development of efficient treatment strategies.
某些药物疗法已被证明对心脏和肾脏结局均有效。尽管风险预测在治疗决策中很重要,但很少有研究评估复合心血管和肾脏结局的预测模型。
本研究纳入了来自全国慢性肾脏病队列的2,195,341名韩国成年人以及一般人群的代表性样本,并进行了9年的随访。本研究评估了主要心血管事件或肾脏疾病进展的复合预测模型,该模型包括蛋白尿和估算肾小球滤过率(eGFR)和/或传统心血管疾病预测指标。
在包含年龄、性别和传统预测指标的复合结局模型中加入蛋白尿和eGFR,C统计量增加了0.0459,而在年龄、性别、蛋白尿和eGFR模型中加入传统预测指标,C统计量增加了0.0157。在糖尿病或高血压参与者中,根据合并的汇总队列方程(PCEs)和肾脏病:改善全球预后(KDIGO)风险类别计算年龄和性别调整后的发病率时,在所有KDIGO高风险或非常高风险类别以及KDIGO中度(或低)风险且PCEs 10年风险≥10%(或≥20%)的类别中,观察到每1000人年≥10的发病率,占糖尿病患者的36%和高血压患者的18%。
本研究有力地支持了KDIGO风险矩阵与传统心血管风险评分相结合用于预测复合心血管和肾脏结局的实用性,并提供了与制定有效治疗策略相关的流行病学数据。